Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | ITK | Q08881 | 4/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27075631 | 0.83 | DAO (0.45) | GSK3BCYP19A1MAPK13RAF1MAPK9 | |
| SCHEMBL308319 | 0.81 | GSK3B (0.61) | GSK3BCYP19A1AURKAAURKBNPC1 | |
| SCHEMBL29470995 | 0.81 | GSK3B (0.61) | GSK3BCYP19A1AURKAAURKBNPC1 | |
| SCHEMBL28221040 | 0.77 | RAB9A (0.53) | GSK3BCYP19A1AURKAAURKBNPC1 | |
| SCHEMBL701368 | 0.77 | CYP19A1 (0.59) | GSK3BCYP19A1AURKAAURKBNPC1 | |
| SCHEMBL31626826 | 0.77 | CYP19A1 (0.59) | GSK3BCYP19A1AURKAAURKBNPC1 | |
| SCHEMBL26127750 | 0.75 | GSK3B (1.00) | GSK3BCYP19A1AURKAAURKBNPC1 | |
| SCHEMBL14764843 | 0.75 | GSK3B (0.51) | GSK3BCYP19A1AURKAAURKBNPC1 | |
| SCHEMBL7640854 | 0.75 | GSK3B (0.68) | GSK3BCYP19A1AURKAAURKBNPC1 | |
| SCHEMBL2062264 | 0.75 | NPC1 (0.71) | GSK3BCYP19A1AURKAAURKBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283922-A | Preparation method of 4-indolopyrimidine biaryl compound | 新天地医药技术研究院(郑州)有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-113582976-B | Deuterated 2-substituted aniline-4-indolyl pyrimidine derivative and preparation method and application thereof | 郑州大学 | 2023-03-17 | — | — | CN | claimed |
| CN-116283922-A | Preparation method of 4-indolopyrimidine biaryl compound | 新天地医药技术研究院(郑州)有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116283922-A | Preparation method of 4-indolopyrimidine biaryl compound | 新天地医药技术研究院(郑州)有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113582976-B | Deuterated 2-substituted aniline-4-indolyl pyrimidine derivative and preparation method and application thereof | 郑州大学 | 2023-03-17 | — | — | CN | disclosed |
| CN-113582976-B | Deuterated 2-substituted aniline-4-indolyl pyrimidine derivative and preparation method and application thereof | 郑州大学 | 2023-03-17 | — | — | CN | disclosed |
| CN-113582976-B | Deuterated 2-substituted aniline-4-indolyl pyrimidine derivative and preparation method and application thereof | 郑州大学 | 2023-03-17 | — | — | CN | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | GSK3B 53/4885CYP19A1 588/4885AURKA 288/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | GSK3B 53/4885CYP19A1 588/4885AURKA 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.